What should I pay attention to when using Daprodustat?
Daprodustat (Daprodustat) is a new type of oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), mainly used to treat chronic kidney disease-related anemia. It improves anemia symptoms by stimulating the production of endogenous erythropoietin (EPO). Although the drug has shown good efficacy and safety in clinical trials, there are still some key precautions that require the attention of patients and doctors during actual use.
Patients' underlying diseases and cardiovascular status need to be assessed before using dapostat, especially in patients with hypertension, heart failure, or a history of stroke. Dapinostat may increase hemoglobin levels, which if increased too rapidly may increase the risk of cardiovascular events. Therefore, hemoglobin, blood pressure, electrolytes and renal function need to be monitored regularly during treatment to avoid complications caused by drugs.
Daprostat is closely related to iron metabolism. During treatment, it is necessary to ensure that the patient's iron reserves are sufficient, otherwise the efficacy of the drug may be affected. Serum iron, transferrin saturation, and serum ferritin levels should be monitored regularly. If functional iron deficiency occurs, your doctor may recommend oral or intravenous iron supplementation. In addition, the drug may interact with other drugs for the treatment of anemia (such as EPO for injection), and it is not recommended to use them together unless specifically directed by a doctor.
Special populations such as pregnant women, lactating women, and children should use daprostat with caution because there is currently a lack of sufficient safety data. If you have unexplained headache, chest pain, edema, rash or visual changes during medication, you should seek medical attention immediately. Overall, dapostat provides a new oral treatment option for patients with anemia in chronic kidney disease, but it must be strictly monitored and used under the guidance of a professional doctor to maximize the efficacy and reduce risks.
Reference materials:https://en.wikipedia.org/wiki/Daprodustat
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)